Seres Therapeutics, Inc.
MCRB
$4.54
$0.061.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 736.00K | 358.00K | 438.00K | 351.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 736.00K | 358.00K | 438.00K | 351.00K | -- |
| Cost of Revenue | 9.14M | 13.20M | 12.28M | 13.35M | 14.63M |
| Gross Profit | -8.41M | -12.84M | -11.84M | -13.00M | -14.63M |
| SG&A Expenses | 7.06M | 8.07M | 7.54M | 9.48M | 10.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.20M | 21.27M | 19.82M | 22.83M | 24.88M |
| Operating Income | -15.47M | -20.91M | -19.38M | -22.48M | -24.88M |
| Income Before Tax | 4.58M | -19.91M | -15.34M | 8.20M | -19.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.58M | -19.91M | -15.34M | 8.20M | -19.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.58M | -19.91M | -15.34M | 8.20M | -19.86M |
| EBIT | -15.47M | -20.91M | -19.38M | -22.48M | -24.88M |
| EBITDA | -14.80M | -20.13M | -18.42M | -21.43M | -23.82M |
| EPS Basic | 0.47 | -2.08 | -1.66 | 0.94 | -2.27 |
| Normalized Basic EPS | -0.94 | -1.30 | -1.12 | -1.36 | -1.43 |
| EPS Diluted | 0.47 | -2.08 | -1.66 | 0.94 | -2.27 |
| Normalized Diluted EPS | -0.94 | -1.30 | -1.12 | -1.36 | -1.43 |
| Average Basic Shares Outstanding | 9.71M | 9.58M | 9.23M | 8.76M | 8.74M |
| Average Diluted Shares Outstanding | 9.71M | 9.58M | 9.23M | 8.77M | 8.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |